Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3086850
Max Phase: Preclinical
Molecular Formula: C157H240N40O46
Molecular Weight: 3423.88
Molecule Type: Unknown
Associated Items:
ID: ALA3086850
Max Phase: Preclinical
Molecular Formula: C157H240N40O46
Molecular Weight: 3423.88
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(C)[C@H](NC(=O)C(NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](C)NC(=O)C(NC(=O)[C@H](Cc1ccccc1)NC(=O)C(NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)C(NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)C(NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1c[nH]cn1)C(C)(C)C(=O)O)[C@@H](C)O)C(C)(C)C)C(C)C)C(C)(C)C)C(C)(C)C(=O)O)C(C)(C)C)C(C)(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)C(C)(C)C(=O)O
Standard InChI: InChI=1S/C157H240N40O46/c1-75(2)109(189-129(220)100(66-108(208)209)182-135(226)103(73-200)187-143(234)114(153(16,17)18)193-131(222)97(61-82-41-30-28-31-42-82)183-139(230)111(81(9)201)188-106(205)70-169-140(231)116(155(22,23)147(238)239)195-123(214)80(8)172-124(215)89(160)65-86-68-165-74-170-86)138(229)186-102(72-199)136(227)185-101(71-198)134(225)181-96(63-84-50-52-87(202)53-51-84)130(221)192-113(152(13,14)15)142(233)179-94(55-57-107(206)207)125(216)168-69-105(204)175-95(54-56-104(161)203)126(217)173-77(5)120(211)171-78(6)121(212)177-92(47-36-38-58-158)127(218)197-118(157(26,27)149(242)243)146(237)184-98(62-83-43-32-29-33-44-83)132(223)191-112(151(10,11)12)141(232)174-79(7)122(213)180-99(64-85-67-167-90-46-35-34-45-88(85)90)133(224)194-115(154(19,20)21)144(235)190-110(76(3)4)137(228)178-93(48-37-39-59-159)128(219)196-117(156(24,25)148(240)241)145(236)176-91(119(162)210)49-40-60-166-150(163)164/h28-35,41-46,50-53,67-68,74-81,89,91-103,109-118,167,198-202H,36-40,47-49,54-66,69-73,158-160H2,1-27H3,(H2,161,203)(H2,162,210)(H,165,170)(H,168,216)(H,169,231)(H,171,211)(H,172,215)(H,173,217)(H,174,232)(H,175,204)(H,176,236)(H,177,212)(H,178,228)(H,179,233)(H,180,213)(H,181,225)(H,182,226)(H,183,230)(H,184,237)(H,185,227)(H,186,229)(H,187,234)(H,188,205)(H,189,220)(H,190,235)(H,191,223)(H,192,221)(H,193,222)(H,194,224)(H,195,214)(H,196,219)(H,197,218)(H,206,207)(H,208,209)(H,238,239)(H,240,241)(H,242,243)(H4,163,164,166)/t77-,78-,79-,80-,81+,89-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,109-,110-,111-,112?,113?,114?,115?,116?,117?,118?/m0/s1
Standard InChI Key: QFFFERPCYSLUQD-IYCBLNKJSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 3423.88 | Molecular Weight (Monoisotopic): 3421.7670 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Heard KR, Wu W, Li Y, Zhao P, Woznica I, Lai JH, Beinborn M, Sanford DG, Dimare MT, Chiluwal AK, Peters DE, Whicher D, Sudmeier JL, Bachovchin WW.. (2013) A general method for making peptide therapeutics resistant to serine protease degradation: application to dipeptidyl peptidase IV substrates., 56 (21): [PMID:24044354] [10.1021/jm400423p] |
Source(1):